APLS
Apellis Pharmaceuticals Inc Earnings
$33.32
Earnings Summary
Revenue | $196.83Mn |
Net Profits | $-57.45Mn |
Net Profit Margins | -29.19% |
Apellis Pharmaceuticals Inc’s revenue jumped 98.45% since last year same period to $196.83Mn in the Q3 2024. On a quarterly growth basis, Apellis Pharmaceuticals Inc has generated -1.43% fall in its revenue since last 3-months.
Apellis Pharmaceuticals Inc’s net profit jumped 59.04% since last year same period to $-57.45Mn in the Q3 2024. On a quarterly growth basis, Apellis Pharmaceuticals Inc has generated -52.55% fall in its net profits since last 3-months.
Apellis Pharmaceuticals Inc’s net profit margin jumped 79.36% since last year same period to -29.19% in the Q3 2024. On a quarterly growth basis, Apellis Pharmaceuticals Inc has generated -54.76% fall in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
Earnings per share (EPS) estimates of the Apellis Pharmaceuticals Inc post its latest quarter earningsEPS Estimate Current Year | -0.54 |
Apellis Pharmaceuticals Inc’s earning per share (EPS) estimates for the current year stand at -0.54.
Key Ratios
Key ratios of the Apellis Pharmaceuticals Inc post its Q3 2024 earningsEarning Per Share (EPS) | -0.46 |
Apellis Pharmaceuticals Inc’s earning per share (EPS) jumped 60.48% since last year same period to -0.46 in the Q3 2024. This indicates that the Apellis Pharmaceuticals Inc has generated 60.48% annual rate of jump in its earning per share (EPS) in the last 4 quarters.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2024-11-05 | -0.3 | -0.46 | -54.13% |
2024-05-07 | -0.47 | -0.42 | 10.64% |
2024-08-01 | -0.32 | -0.28 | 12.5% |
₹0 US Stocks a/c Opening Fee